

Index

21 CFR (Code of Federal Regulations), 30
510(k) premarket notification process, 229, 307

A

abbreviated new drug application (ANDA), 169
aberrant lymphatic function, 173
absorption spectrum, 93
academia, 286
academic–industry collaborations, 288
accuracy, 301
adenomatous polyps, 257
adverse event (AE), 227
AGR2, 253
American Association of Physicists in Medicine (AAPM), 52
applied research, 16
associate members, NTR, 22
autofluorescence, 165
axillary lymph nodes, 168

B

B-scan, 97
basal cell carcinoma, 257
batch release, 33
bench to bedside, 3, 10
bioinformatics analysis, 176
biological matrix, 301
biological product, 167

biologics license application (BLA), 69
biomarkers, 286
biophotonics, 2
biostatistician, 213
body lumens, 15
breast-cancer-related lymphedema (BCRL), 174

C

caBIG[®], 52–53
cancer care, 14
Cancer Imaging Archive (NCIA), 54
cancer staging, 159
cancer survival, 172, 174
Cancer UK cooperative agreement, 53
Case Report Form (CRF), 324
CDH1 mutation, 256
Center for Devices and Radiological Health (CDRH), 169
Center for Drug Evaluation and Research (CDER), 168
Centers for Medicare & Medicaid Services (CMS), 5, 168, 216
certificate of analysis, 214
CFR compliance, 180
charge-coupled device (CCD), 166, 185
chelators, 163

- Chemistry Probes and Guided Therapies Core, 21
- Chemistry, Manufacturing, and Controls (CMC), 225, 317
- chlorotoxin, 259
- chylothorax, 175–176
- chyloous ascites, 176
- circulating tumor cells (CTCs), 247
- clinical acceptance, 290–291
- clinical adoption, 190
- Clinical and Translational Science Awards (CTSA) program, NIH, 160
- clinical efficacy research, 4
- clinical outcomes research, 5
- clinical practice, 14
- clinical research associate, 213
- clinical studies, 288
- clinical trial registration, 327
- clinician investigator, 213
- Code of Federal Regulations (CFR), 298
- colloid, 129
- colonoscopy, 205
- colorectal cancer, 204
- combination products, 75, 167, 299
- commercialization process, 286
- compassionate-use study, 175
- compliance, 292
- computed tomography (CT), 16, 285
- conflict of interest (COI), 215
- confocal endomicroscope, 251
- congenital lymphatic disorders, 176
- consensus, 17
- continuous-wave studies, 182
- contrast agents, 15
- cores, 15
- cost accountability, 36
- COX-2 inhibitors, 253
- Current Procedural Terminology (CPT), 216
- cyclooxygenase-2 (COX-2), 50
- cypate, 46, 117
- D**
- Data Safety Monitoring Board (DSMB), 230
- device history file, 41
- device sensitivity, 182
- Digital Imaging and Communications in Medicine (DICOM), 53
- disputes, 292
- disruptive technology, 290
- Doppler images, 89
- drug and device regulations, 69
- Drug Master File (DMF), 170
- drug product, 318
- drug substance, 318
- dual-axis confocal (DAC) endomicroscope, 221
- dual-axis confocal (DAC) endomicroscope, fluorescence-based, 244
- dual labeling, 47
- E**
- E-cadherin, 256
- electron-multiplying CCD (EMCCD), 185
- endoscopic Raman spectroscopy, 255
- engineering requirements, 289
- enhanced permeability and retention (EPR), 187
- environmental analysis requirements, 318
- epithelial cell adhesion molecule (EpCAM), 48, 187
- epithelium growth factor receptor (EGFR), 264
- ethical standards, 292
- F**
- far-red gene reporter, 187
- first-in-human studies, 169
- flow cytometry, 262

- fluorescence, 15, 113
fluorescence diffuse optical tomography (DOT), 112
fluorescence-guided surgery, 24
fluorescence molecular imaging, 165, 186
fluorescence resonance energy transfer (FRET), 255
fluorocoxibs, 52, 254
fluorodeoxyglucose (FDG), 286
fluoroscopy, 285
Food and Drug Administration (FDA), 9, 68, 168, 299
foreign language, material in a, 321
- G**
gain modulation, 182
gamma scintigraphy, 162, 166, 169
Gen III image intensifiers, 181
gold nanobeacons, 126
good laboratory practices (GLP), 8, 305
good manufacturing practices (GMP), 308
Guidance Documents, 298, 309
- H**
Health Insurance Portability and Accountability Act (HIPAA), 231
healthcare industry, 285
healthcare market, 289
healthcare outcome, 290
hemoglobin, 115
Her2-neu, 261
hereditary diffuse gastric cancer, 256
hydroxysuccinimide (NHS)
 chemistry, 189
- I**
IDE submission, 314
IEEE, 52
IFP1.4, 187
image registration, 35
imaging instruments, wide-field, 251
Imaging Workspace, 53
immunoconjugates, 189
in vivo flow cytometry, 262
In Vivo Imaging Workspace and Tissue Banks and Pathology Tools Workspace, 54
IND submission, 314
IND submission, numbering of, 321
IND, financial sponsor of, 179
IND, investigator-initiated, 178
indocyanine green (ICG), 45, 114, 168, 183
industrial partner, 20
inflammatory bowel diseases, 245
Information Technology Core, 21
informed consent, identification of exception from, 321
infrared fluorescent protein (iRFP), 187
installation quality/operational quality (IQ/OQ), 33, 53
Institute of Medicine (IOM), 160
institutional review board (IRB), 68, 175, 227, 326
instrument qualification, 161
Instrumentation and Industrial Relations, 21
integrin receptors, 259
intellectual property, 215, 287, 291
intensified CCD (ICCD), 182
Interagency Council, 168
interference filter leakage, 183
International Society for Magnetic Resonance in Medicine (ISMRM), 52
introductory statement and general investigational plan, 315
investigational device, 167
investigational device exemption (IDE), 75
investigational drug, previous human experience with, 319

- investigational drug service (IDS), 224
- investigational new drug (IND), 72, 167, 213
- investigational new drug (IND) process, 167
- investigational plan, 323
- investigator's brochure, 315
- L**
- labeling, 318
- labels, rules for, 33
- liability, 291
- light source, 165
- limit of detection (LOD), 301
- lower limit of quantification (LLOQ), 301
- lymph node dissection, 172, 186
- lymph nodes, 168
- lymphangiogenesis, 178
- lymphangions, 172
- lymphatic failure, 172
- lymphatic propulsion, 173
- lymphatic pumping, 174
- lymphatic vasculature, 170, 172
- lymphoscintigraphy, 172
- M**
- magnetic resonance imaging, 15, 285
- maleimide functional groups, 189
- manual lymphatic drainage (MLD), 174
- manufacturing requirements, 289
- MAPK/ERK, 177
- master research agreement (MRA), 291
- material transfer agreement (MTA), 215
- Mauna Kea Technologies, 215
- medulloblastoma, 258
- melanin, 115
- MEMS scanner, 250
- metastatic human prostate cancer, 166
- methylene blue (MB), 45, 85
- micro-electro-mechanical system (MEMS), 221
- micro-PET, 166
- micro-SPECT, 166
- microdosage, 167
- molecular imaging, 144
- mouse tumor model, 259
- multidisciplinary activity, 14
- multimodal agents, 116
- multimodal approach, 16
- multimodal imaging, 15
- multimodal platforms, 15
- multimodality chelator (MMC), 48
- N**
- nanoparticles, 120
- National Biomedical Imaging Archive (NBIA), 53
- National Cancer Institute (NCI), 2, 168
- National Institute of Standards and Technology (NIST), 52
- National Institutes of Health (NIH), 286
- Network for Translational Research (NTR), 2, 9-10
- Network for Translational Research Optical Imaging (NTROI), 14
- new drug application (NDA), 69, 307
- new molecular entity (NME), 166
- next-generation sequencing, 176, 190
- NIR optical window, 250
- NIRF imaging, 190
- NIRF imaging agent, 164
- NIRF imaging agents, antibody-based, 168
- NIST certification, 184
- nodal staging, 159

nondisclosure agreement (NDA),
215
Novadaq SPY system, 185
nuclear imaging technologies, 161

O

obstacles to translation, 7
Office of Biospecimens and
Biorepositories (OBBR), 54
Office of Combination Products
(OCP), 168
Office of Technology Transfer
(OTT), 215, 292
optical coherence tomography
(OCT), 24
optical fibers, 15, 109
optical imaging, 15, 285
optical imaging, multispectral, 24
orthotopic model, 187

P

parallel acoustic delay line (PADL),
104
pathologist, 213
pediatric intensive-care physician,
175
pediatric studies, 320
peptides, 209
perfluorocarbon, 120
phantom, solid, 185
phantoms, 36, 42, 169, 183
phantoms, calibration, 43
phantoms, development, 44
phantoms, verification, 44
pharmacology/toxicology study,
225, 319, 318
photoacoustic computed
tomography (PACT), 104
photoacoustic effect, 86
photoacoustic microscopy (PAM),
104
photoacoustic tomography (PAT), 45
photobleaching, 125

PI3K/AKT, 177
piezoelectric (PZT), 221
piston-motion mirror, high-
frequency, 251
plasmon resonance, 125
pneumatic compression device
(PCD), 174
positron emission tomography
(PET), 16, 162, 285
premarket approval (PMA), 69, 307
premarket notification, 307
primary lymphedema, 176
primary mode of action (PMOA),
166
principal investigators, 293
prior investigations, report of, 324
process validation, 301
product development, 289
products, commercially available,
286
protocol, 306, 316
prototype, 285

Q

Qdot[®] 800, 183
qualification, 54
Quality Assurance Unit (QAU), 305
Quantative Imaging Biomarkers
Alliance (QIBA), 52
quantification range, 301
Quantitative Imaging Network
(QIN), 53

R

Radiation Safety Office (RSO), 68
radiation therapy, 172
Radioactive Drug Research
Committee (RDRC), 68, 71
radioactive drugs, 320
Radiological Society of North
America (RSNA), 52
Raman endoscope, 264
Raman imaging system, 265

- RASAI*, 177
recruitment, 179
regioselective conjugation
 approach, 189
registration, 54
regulations, 298
regulatory oversight, 68
regulatory requirements, 289
regulatory strategy, 178
retention samples, 33
rights, licensing, and patents, 292
risk mitigation in
 commercialization, 289
- S**
safety and toxicity studies, 168
safety requirements, 289
saturation of peripheral oxygen
 (SpO₂), 92
scanning cytometer, 261
scanning fiber endoscope, 218
scanning, all-MEMS, 251
scanning, circumferential, 265
scintigraphy, 211
SciPort, 22, 33, 53, 180, 290
selectivity, 301
self-assessment tool, 32
sentinel lymph node (SLN), 46,
 84
serious adverse event (SAE), 227
service requirements, 289
SI units, 43
Siemens Corporate Research
 platform, 180
signal amplification, 15
signal visualization, 15
single-photon-emission counting
 tomography (SPECT), 162-163
Siteman Cancer Center, 88
Society of Nuclear Medicine
 (SNM), 52, 160
SPECT/CT, 117
spectroscopic PAT, 92
- SPIE, 52
SpyGlass[®], 252
SpyGlass[®] fluorescence endoscope,
 252
squamous cell carcinoma, 258
stability, 302
stage-gate approach, 289
standard operating procedure
 (SOP), 33, 223, 306, 324
standards, 161
Standards and Compliance Core,
 21
statement of work (SoW), 291
Steering Committee, NTR, 22
Study Director, 305
subcutaneous tumor model, 187
supplemental NDA (sNDA), 169
surface-enhanced Raman scattering,
 15, 264
surgery, 15
- T**
T1 research, 191
technetium radiocolloid, 169
technology developers, 14
technology development, 16
technology end users, 14
technology optimization, 16
technology transfer agreements, 5
technology validation, 16
time-correlated photon counting
 (TCSP), 164
titanium dioxide, 183
toxicology, 289, 301, 319
traceability matrix, 41
transducer, 96
translational research, 2
Translational Research Working
 Group (TRWG), 14
- U**
U.S. Pharmacopoeia, 298
ultrasonography, 16, 85

ultrasound, 285
ultrasound-based delivery, 253
upper limit of quantification
(ULOQ), 302
usability, 287

V

V Model, 41
validation, 5, 17, 31, 34, 38, 54, 289,
299, 302
Validation and Clinical Studies
Core, 21
validation and verification
(V&V), 38
validation protocols, 169, 188
validation tests, 302, 303
validation, cross-, 301
validation, full, 301
validation, partial, 301

VEGFR, 259
verification, 5, 31, 39, 54
virtual slides, 54
visual intraoperative cues, 186

W

Washington University School of
Medicine, 88
whole-exome sequencing, 177
wiki site, 52

X

x-ray imaging, 285
Xenogen IVIS 200, 254
XIP (eXtensible Imaging
Platform), 55

Z

Zerhouni, Elias, 1